FDC Ltd (FDC)
₹343.75
Mkt cap
₹5,571 Cr
P/E ratio
18.10
P/B
2.25
Div yield
1.46%
ROE
11.20%
ROCE
15.40%
EPS (TTM)
₹18.99
Book value
₹153
52W range
321–487
Sector
Healthcare
Price history
Previous close
FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Some of FDC’s leading brands in India include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl and Mycoderm in the domestic and international markets. [1]
NSE FDCBSE 531599
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−29.39% from high₹344
₹321+7.05% from low₹487
Current
₹343.75
Prev close
₹342.50
Day
+0.36%
Price performance
1D
+0.36%
1W
+3.04%
1M
−4.61%
3M
−9.72%
6M
−6.62%
1Y
−25.93%
YTD
−18.07%
Financials
Revenue, profit & margin
P/E ratio
18.1×
FDC is 48% below the sector median of 35.1×
FDC18.1×
Sector median35.1×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 536 | 486 | 458 | 462 | 638 | 514 | 464 | 492 | 648 | 473 | 465 | 585 | 668 | |
| Expenses | 414 | 410 | 374 | 406 | 492 | 444 | 417 | 438 | 508 | 439 | 412 | 478 | 525 | |
| Operating Profit | 122 | 76 | 84 | 56 | 147 | 70 | 47 | 54 | 140 | 34 | 52 | 106 | 143 | |
| OPM % | 23% | 16% | 18% | 12% | 23% | 14% | 10% | 11% | 22% | 7% | 11% | 18% | 21% | |
| Other Income | 29 | 27 | 25 | 20 | 28 | 35 | 19 | 16 | 36 | 21 | 0 | 50 | 48 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | |
| Depreciation | 10 | 10 | 10 | 10 | 11 | 14 | 13 | 16 | 15 | 15 | 15 | 14 | 15 | |
| Profit before tax | 141 | 93 | 98 | 65 | 163 | 90 | 51 | 53 | 160 | 38 | 36 | 140 | 175 | |
| Tax % | 22% | 25% | 19% | 29% | 27% | 20% | 28% | 27% | 24% | 26% | 22% | 26% | 24% | |
| Net Profit | 110 | 70 | 79 | 46 | 119 | 72 | 37 | 39 | 121 | 28 | 28 | 103 | 132 | |
| EPS in Rs | 6.62 | 4.29 | 4.87 | 2.84 | 7.31 | 4.42 | 2.28 | 2.38 | 7.45 | 1.74 | 1.74 | 6.35 | 8.14 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −4.53% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 5 Aug '26 |
| Earnings day | −4.53% |
| +1 day | −4.58% |
| +5 days | −7.43% |
| +15 days | −11.28% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202669.65%Promoter
Promoters69.65%
FIIs1.40%1.00
DIIs6.31%0.02
Public22.63%0.98
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.77 | 1,86,913 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.17 | 96,254 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| FDC | ₹342.15 | 18.09 | 5,571 | 1.46% | 132 | +9.17% | 668 | +2.97% | 15.35% |
| Median: 159 Co. | ₹423.00 | 35.07 | 2,282 | 0.08% | 13 | +29.60% | 162 | +18.62% | 15.04% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts16
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Sep - Newspaper Publication of the convening of the 86th Annual General Meeting of the Company.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 3 SepBusiness Responsibility and Sustainability Reporting (BRSR) 1 Sep - Submitted Business Responsibility and Sustainability Report for FY 2025-26 under Regulation 34.Intimation Of Book Closure And Cut-Off Date In Accordance With Regulation 42 Of SEBI (Listing Obligations And Disclosure Requirement) 2015 1 Sep - FDC 86th AGM on September 24, 2026; book closure September 17-23 and cut-off September 16.Reg. 34 (1) Annual Report. 1 Sep